Alveus CEO Raj Kannan says its ALV-100 is built for maintenance, possibly dosed quarterly. Viking reports 97% of weight loss held on every-other-week VK2735.
Recap by typeshit. Full story at Yahoo Finance.
Pratt, a psychology professor who studies the circuits behind food motivation, walks through what neuroscience shows about these drugs.
Lilly's pill had major heart events in 4.2% of patients vs 5.0% on insulin glargine. The Clinical Trial Vanguard argues rivals now need to show benefit, not just safety.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
People with conditions the drugs are approved to treat get sent back to Part D, where copays can hit $200 to $600 a month. One New Jersey patient was rejected despite a BMI of 42.
A consumer review of Lemonaid's telehealth weight loss service, which manages GLP-1 injections and prescriptions for patients paying out of pocket.
Loading…